• KX2-391 dihydrochloride: Assay Guide

  2026-08-20

  A scenario-based guide to using KX2-391 dihydrochloride in cell viability, proliferation, cytotoxicity, HBV, and BoNT/A workflows. It explains how SKU A3535 supports concentration selection, solvent control, mechanism-aware interpretation, and practical product evaluation.

• Fluorescein TSA Fluorescence System Kit Workflow

  2026-08-19

  Learn how to apply tyramide-based fluorescence amplification to low-abundance targets in IHC, ICC, and ISH. This workflow connects the kit’s spatially retained signal to metastatic HNSCC research while providing practical setup, optimization, and troubleshooting guidance.

• Nelfinavir Mesylate: Applied Research Workflows

  2026-08-19

  Nelfinavir Mesylate supports both cell-based HIV-1 protease inhibition assays and mechanistic studies of DDI2–NFE2L1 control of ferroptosis. This guide translates its biochemical potency, formulation properties, and cross-domain use into practical workflows, controls, and troubleshooting decisions.

• Paroxetine Mesylate: Applied Research Workflows

  2026-08-18

  Paroxetine Mesylate supports a practical research strategy spanning SERT pharmacology, enzyme-interaction studies, kinase profiling, and colorectal cancer models. This guide translates its multi-target profile into assay setup, protocol parameters, comparative applications, and troubleshooting decisions.

• From PLAC1 Biology to Smarter Cancer Screening

  2026-08-18

  A translational framework for moving from PLAC1-associated biology in clear cell renal cell carcinoma to biomarker-aware chemical screening. The article explains how the DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) can support mechanism-focused hit discovery, orthogonal validation, pathway mapping, and more disciplined decisions about preclinical relevance.

• Lysosomal β-Galactosidase Staining in HNSCC

  2026-08-17

  Learn how the Lysosomal β-Galactosidase Staining Kit can strengthen senescence interpretation in HNSCC cisplatin-resistance studies. This guide connects lysosomal enzyme imaging with the SLC25A1–H3K27ac mechanism while clarifying controls, assay limits, and practical workflow decisions.

• Prestained Protein Marker for LARP1 Workflows

  2026-08-17

  Build clearer LARP1 ribosome-fractionation and immunoblot workflows with a triple-color, EDTA-free ladder spanning low- and high-molecular-weight targets. The marker combines real-time gel tracking, transfer verification, and compatibility with Phosbind and fluorescent membrane imaging in one practical standard.

• Sodium Ascorbate: ROS Strategy for Translational Oncology

  2026-08-16

  Sodium Ascorbate is a mineral salt of ascorbic acid that can serve as a defined redox perturbation in cancer models. This thought-leadership analysis connects its ROS-driven tumor-cell effects with emerging biomarker frameworks for immunotherapy response, while separating established evidence from exploratory translational hypotheses.

• CAF–ANGPTL4–IQGAP1 Axis in Prostate Cancer

  2026-08-15

  This study identifies a paracrine ANGPTL4–IQGAP1 pathway through which cancer-associated fibroblasts enhance mitochondrial biogenesis, oxidative phosphorylation, and chemotherapy resistance in prostate cancer. Its integrated proteomic, metabolomic, interaction, and pharmacologic evidence supports IQGAP1 and CAF-derived signaling as potential research targets for improving docetaxel responsiveness.

• Coronavirus Macrodomain Counters PARP Antiviral Immunity

  2026-08-14

  Grunewald et al. showed that coronavirus macrodomains protect viral replication by countering host PARP-dependent ADP-ribosylation. Pharmacologic inhibition and selective depletion of PARP12 and PARP14 exposed a virus–host interaction in which PARP activity restricts macrodomain-defective coronavirus and supports interferon production.

• Thrombin B Chain Fragment: Assay Workflows

  2026-08-14

  Use the sequence-defined Thrombin B Chain Fragment as an analytical, binding, and specificity control—not as a substitute for catalytically complete thrombin. This guide translates rigorous protease-screening principles into practical workflows for coagulation, platelet, vascular, and orthogonal assay development.

• Artesunate: From Cell Fate Readouts to Translation

  2026-08-13

  Artesunate is more than a cytotoxicity benchmark: it is a mechanistically informative artemisinin derivative for resolving ferroptosis, pyroptosis-related signaling, and AKT/mTOR biology in cancer models. This thought-leadership guide shows how translational researchers can pair Artesunate with better viability measurements, model selection, and disciplined interpretation.

• CD28–ARS2 Control of CD8+ T-Cell Metabolism

  2026-08-13

  The reference study identifies a CD28–ARS2 signaling axis that reshapes alternative splicing of PKM, favoring PKM2 and enabling metabolic flexibility in activated CD8+ T cells. Its findings connect costimulatory signaling to glucose utilization, interferon-γ production, and antitumor activity through a mechanism that is distinct from canonical CD28–PI3K signaling.

• Mavorixafor Hydrochloride: CXCR4 Antagonist

  2026-08-12

  Mavorixafor hydrochloride, also called AMD-070 hydrochloride, is an oral CXCR4 antagonist that disrupts CXCR4/CXCL12-dependent cell trafficking. Clinical evidence is strongest in WHIM syndrome, while anti-HIV research and Waldenström's macroglobulinemia applications remain distinct translational contexts.

• Deferasirox at the Iron–Lysosome Interface

  2026-08-12

  Deferasirox is an oral iron chelator whose effects extend beyond iron removal into mitochondrial ROS, inflammatory signaling, and myeloid differentiation. This article develops a lysosome-centered assay framework inspired by TCF25-mediated ferritinophagy, helping researchers distinguish iron depletion from lysosome-dependent cell death.

8026 records 9/536 page Previous Next First page 上5页 678910 下5页 Last page